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Abstract
Background: Previous reports of site-directed deletion analysis on gamma (γ)-phage lysin protein
(PlyG) have demonstrated that removal of a short amino acid sequence in the C-terminal region
encompassing a 10-amino acid motif (190LKMTADFILQ199) abrogates its binding activity specific
to the cell wall of Bacillus anthracis. Whether short synthetic peptides representing the10-amino
acid PlyG putative binding motif flanked by surrounding N- and C-terminal residues also selectively
bind to the bacterial cell wall has not been evaluated. If such peptides do demonstrate selective
binding to the cell wall, they could serve as bio-probes towards developing detection technologies
for B. anthracis. Furthermore, by using B. anthracis (Sterne, 34F2), an animal vaccine and B. cereus-
4342, a γ-phage susceptible rare strain as surrogates of B. anthracis, development of proof-of-
concepts for B. anthracis are feasible.
Results:  Using four different methods, we evaluated six synthetic peptides representing the
putative binding motif including flanking sequences (PlyG-P1 through P6) for the bacterial cell wall
binding capacity. Our analysis identified PlyG-P1, PlyG-P3 and PlyG-P5 to have binding capability to
both B. anthracis (Sterne, 34F2) and B. cereus-4342. The peptides however did not bind to B. cereus-
11778, B. thuringiensis, and B. cereus-10876 suggesting their specificity for B. anthracis-Sterne and B.
cereus-4342. PlyG-P3 in combination with fluorescent light microscopy detected even a single
bacterium in plasma spiked with the bacteria.
Conclusion:  Overall, these studies illustrate that the short 10-amino acid sequence
'LKMTADFILQ' in fact is a stand-alone bacterial cell wall-binding motif of PlyG. In principle,
synthetic peptides PlyG-P1, PlyG-P3 and PlyG-P5, especially PlyG-P3 coupled with Qdot-
nanocrystals are useful as high-sensitivity bio-probes in developing detection technologies for B.
anthracis.
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Background
Spore forms of Bacillus anthracis once inhaled, germinate
and multiply rapidly in lymph nodes that are in close
proximity to lungs. Subsequently the bacteria and its
lethal toxin circulate into the blood stream, thereby caus-
ing death to the exposed subjects if untreated on time [1-
5]. Because of this lethal effect on humans and animals, B.
anthracis  is classified as a category-A bioweapon [6-9].
There are a number of double-stranded DNA bacteri-
ophages that specifically bind, infect and lyse host bacte-
ria through the action of a family of enzymes called lysins
that they encode [10-12]. One such enzyme, the γ-phage
derived lysin PlyG (Phage lysin-Gamma), was previously
shown both in vitro and in a Balb/c mouse model to selec-
tively search and kill both B. anthracis and a rare variant
susceptible to γ-phage, B. cereus-4342 [4].
The PlyG like other members of the lysin family contains
two domains, an N-terminal catalytic domain and a C-ter-
minal domain that demonstrates high degree of binding
specificity to the cell wall peptidoglycans of B. anthracis
and its nonlethal surrogates [13-15]. Previous analysis of
PlyG C-terminal region suggested that a domain spanning
residues 156 to 233 of PlyG is sufficient for binding to the
B. anthracis cell and useful as a probe in detecting the bac-
teria [16]. Deletion analysis of PlyG 156–233 region fur-
ther indicated that a PlyG polypeptide lacking amino
acids 190 to 199 (LKMTADFILQ) lost its ability to bind to
the bacteria, suggesting that this short region imparts
binding activity to the PlyG polypeptide [17]. By further
mutational analysis, both L190 and Q199 residues of
LKMTADFILQ sequence proved to be important for the
binding activity of PlyG [17]. In all these studies, larger
polypeptides of PlyG served as probes to detect the bacte-
ria. However, whether short synthetic peptides containing
LKMTADFILQ amino acid sequence alone can selectively
bind to the bacteria with similar specificity or the 10-
amino acid sequence imparts cell wall binding capability
only in the context of larger PlyG protein is not known. If
the former turns out to be true by experimental verifica-
tion, then such short synthetic peptides will be useful in
developing novel detection methods for B. anthracis by
using its known surrogates, B. anthracis (Sterne, 34F2) vac-
cine strain and another γ-phage susceptible rare bacillus
strain, B. cereus-4342. The advantage with short synthetic
peptides is that large quantities of peptides in pure form
can be synthesized. Whereas, achieving purity of larger
recombinant proteins often associates with inherent prob-
lems such as protein denaturation and misfolding, lead-
ing to loss of function [18,19].
In this report, using four different methods, we evaluated
six synthetic peptides representing the 10-amino acid
PlyG putative binding motif and its variant forms for the
bacterial cell wall binding capacity. We successfully iden-
tified three synthetic peptides that are effective in selec-
tively binding to B. cereus-4342 and B. anthracis (Sterne
34F2) in spiked plasma.
Results
Synthetic PlyG peptides that include LKMTADFILQ 
residues demonstrate binding to both B. cereus-4342 and 
vaccine strain of B. anthracis (Sterne)
To test whether short synthetic peptide LKMTADFILQ by
itself can bind to the cell wall of B. cereus-4342 and B.
anthracis  (Sterne), we synthesized six peptides ranging
between 10–20-mers within the C-terminal region of
PlyG between amino acid positions 185 to 204, which
encompass residues 190LKMTADFILQ199 or its variants
where L190 and Q199 had substitutions. Figure 1 illus-
trates the description of each peptide. We examined the
binding capacity of these peptides to B. cereus-4342, B.
anthracis-Sterne,  B. cereus-11778,  B thuringiensis-10792
and B. cereus-10876 by four independent methods: 1. dot-
blot assay, 2. ELISA method, 3. fluorometry and 4. Fluo-
rescence-microscopy. In the later two methods, using bac-
teria-spiked plasma as the detection medium, the peptide
bound to bacteria was detected by Qdot-nanocrystal cores
conjugated with streptavidin.
Dot-blot based binding specificity analysis of the peptides
Our results revealed that peptides PlyG-P1, P3, and P5
selectively bind to B. cereus-4342 and B. anthracis-Sterne
in the dot-blot assay while peptides PlyG-P2, P4 and P6
did not do so (Figure 2). None of the six peptides bound
to B. cereus-11778, B. thuringiensis and B. cereus-10876,
although these strains belong to Bacillus  group, which
clearly demonstrates the binding specificity of the PlyG-
based peptides for B. anthracis-Sterne and B. cereus-4342.
ELISA based binding analysis of the peptides
Since PlyG peptides demonstrated specific binding to
both B. cereus-4342 and B. anthracis-Sterne in the dot blot
Schematic representation of PlyG peptides indicating amino  acid (aa) position 185–204 of PlyG Figure 1
Schematic representation of PlyG peptides indicating 
amino acid (aa) position 185–204 of PlyG. Top 
sequence Represents PlyG amino acid sequence from 185–
204 within the C-terminal 156–233 region. Residues under-
lined at position 190 and 199 in peptide 2 and 6 indicate 
amino acid substitutions at that position.
PlyG seq GALTSLKMTADFILQSDGLT
PlyG-P1      GALTSLKMTADFILQSDGLT
PlyG-P2      GALTSAKMTADFILASDGLT
PlyG-P3      GALTSLKMTADFILQ-----
PlyG-P4           LKMTADFILQSDGLT
PlyG-P5      -----LKMTADFILQ-----
PlyG-P6      -----AKMTADFILA-----
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assay, we further evaluated the binding ability of these
peptides to the bacteria in an ELISA based assay. Results of
this assay method illustrated that peptide PlyG-P1 and
PlyG-P3 are strong binders (P < 0.05) to B. cereus-4342
and B. anthracis-Sterne while PlyG-P5 has relatively lower
binding; binding of rest of the peptides including the
mutant forms were below the detection level (Figure 3). In
this assay, none of the six peptides demonstrated binding
to B. cereus-11778, B. thuringiensis and B. cereus-10876 as
is the case with the dot-blot method. Statistical evaluation
of the ELISA results revealed that binding of PlyG-P1,
PlyG-P3 and PlyG-P5 to B. cereus-4342 and B. anthracis-
Sterne was significantly higher (P < 0.05) than the binding
of PlyG-P2, PlyG-P4 and PlyG-P6 to the same bacteria.
Streptavidin-conjugated Quantum Dot (QD)-based 
binding specificity analysis of the peptides
All six PlyG peptides (P1-P6) were incubated individually
with B. cereus-4342, B. anthracis-Sterne, B. cereus-11778, B.
thuringiensis, and B. cereus-10876 cultures and binding of
each peptide to the bacteria was detected using Qdot-
nanocrystal cores conjugated with streptavidin. Analysis
of human plasma spiked with the bacterial suspensions in
a micro-well plate was performed using a fluorescence
plate reader (Synergy 4™, Biotek, USA). Excitation was set
to a spectral range of 360–485 nm and emission was at
605 nm. Fluorometric analysis revealed that in this exper-
imental setting, PlyG-P1, PlyG-P3 and PlyG-P5 were able
to bind to B. cereus-4342 and B. anthracis-Sterne as indi-
cated by the significantly higher levels of fluorometric
counts (P < 0.05) compared to the samples containing
PlyG-P2, P4 and P6. The analysis also confirmed that
binding of peptides PlyG-P1, PlyG-P3 and PlyG-P5 to B.
cereus-4342 and B. anthracis-Sterne was highly specific, as
they did not cross-react with B. cereus-11778, B. thuring-
iensis, and B. cereus-10876 (Figure 4).
Fluorescence microscopy combined with QD-based 
binding sensitivity and specificity analysis of PlyG-P3
Experiments so far described in this report indicated that
among the six peptides evaluated, PlyG-P3 was the best
binder with significantly higher binding (P < 0.05) com-
pared to others. Therefore, we further attempted to con-
firm this peptide's binding and the limit of detection by a
visual method such as fluorescence microscopy. Briefly,
human plasma samples spiked with ten-fold dilutions of
Bacillus cultures were incubated with PlyG-P3 peptide for
each dilution. Following incubation, the bacteria-peptide
complex was detected with the Qdots under a fluores-
cence microscope (Nikon Eclipse TE2000-U, USA). The
analysis clearly identified that PlyG-P3 peptide specifi-
cally binds to the outer surface of B. cereus-4342 and B.
anthracis-Sterne bacterium, providing visual evidence that
Dot-blot analysis of peptides binding to B. cereus-4342, B.  anthracis-Sterne, B. cereus-11778, B. thuringiensis, and B.  cereus-10876 Figure 2
Dot-blot analysis of peptides binding to B. cereus-
4342, B. anthracis-Sterne, B. cereus-11778, B. thuring-
iensis, and B. cereus-10876. Bacterial suspensions (103 
CFU) were blotted on to the membrane and the membrane 
was cut in to strips. The membrane strips were incubated 
individually with the six PlyG peptides. Following streptavi-
din-HRP incubation, the membranes were incubated with 
diaminobenzidine (DAB) reagent and peptide binding was 
detected by development of brown spots.
ELISA-based analysis of PlyG peptide binding to B. cereus- 4342, B. anthracis-Sterne, B. cereus-11778, B. thuringiensis, and  B. cereus-10876 Figure 3
ELISA-based analysis of PlyG peptide binding to B. 
cereus-4342, B. anthracis-Sterne, B. cereus-11778, B. 
thuringiensis, and B. cereus-10876. Individual wells of a 
96-well microplate were coated with desired bacterial sus-
pensions (103 CFU) and incubated with biotinylated PlyG 
peptides prior to incubation with streptavidin-HRP. Color 
was developed by adding TMB. Optical density of the reac-
tions were measured at 490 nm using a microplate reader. 
Error bars indicate the SD from three independent experi-
ments. Statistically significant difference (P <0.05) is repre-
sented by (*).
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PlyG-P3 peptide in combination with the Qdot labeling
method clearly enhances the detection sensitivity to a sin-
gle bacterium in the spiked plasma (Figure 5).
Discussion
In this study, our goal was to refine the previously known
B. anthracis cell wall binding C-terminal 156–233 region
of γ-phage lysin PlyG by employing the minimal sequence
as a synthetic peptide that would be useful as a bioprobe
for the detection of B. anthracis. We have utilized an ani-
mal vaccine B. anthracis (Sterne) and a rare γ-phage sus-
ceptible  B. cereus-4342 as surrogates for the strain, B.
anthracis with respect to the cell wall binding ability of the
synthetic peptides. In this analysis, we have also included
other bacillus members, B. cereus-11778, B. thuringiensis
and B. cereus-10876 to serve as controls to illustrate the
binding specificity of the synthetic peptides to the two sur-
rogates. Site-directed deletion analysis of PlyG in the past
has demonstrated that deletion of a short amino acid
sequence in the C-terminal region encompassing a 10-
amino acid motif (190LKMTADFILQ199) abrogated its
binding activity targeted to the cell wall of Bacillus anthra-
cis. However, whether short synthetic peptides containing
the 10-amino acid putative binding motif flanked by sur-
rounding N- and C-terminal residues also selectively bind
to the bacterial cell wall has not been evaluated.
As a first step, we synthesized six peptides derived from
the PlyG lysin polypeptide sequence encompassing the
185GALTSLKMTADFILQSDGLT204 amino acid region
[17]. The synthetic peptides were analyzed for their bacte-
rial cell binding capability by using two surrogate strains
in spiked plasma as a model for B. anthracis detection
under bio-safety level 2 (BSL2) conditions. Previously it
was shown that PlyG protein bound to both B. cereus-
4342 and B. anthracis with equal affinity due to the iden-
Streptavidin-conjugated Quantum Dot (QD) based analysis  of PlyG peptides binding to bacteria Figure 4
Streptavidin-conjugated Quantum Dot (QD) based 
analysis of PlyG peptides binding to bacteria. Human 
plasma was spiked with B. cereus-4342, B. anthracis-Sterne, B. 
cereus-11778, B. thuringiensis and B. cereus-10876. Each PlyG 
peptide (P1-P6) were incubated with the bacteria. Following 
incubation, the samples were centrifuged and resuspended in 
PBS. Streptavidin-conjugated quantum-dots (QDs) were then 
added to the sample (bacteria-peptide complex) and analyzed 
by a fluorescence plate reader (Synergy 4TM, Biotek, USA) 
with excitation spectrum set at 360–485 nm and emission 
spectrum at 605 nm. Error bars indicate the SD from 3 inde-
pendent experiments. Statistically significant difference (P < 
0.05) is represented by (*).
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Microscopy-based sensitivity analysis of PlyG-P3 peptide  binding Figure 5
Microscopy-based sensitivity analysis of PlyG-P3 pep-
tide binding. Bacterial cultures of Bacillus cereus 4342, B. 
anthracis-Sterne, B. cereus-11778, B. thuringiensis, and B. 
cereus-10876 were incubated with PlyG-P3 and the complex 
was detected by incubating with strepatividin-conjugated 
quantum dots. Peptide binding was detected by the fluoresc-
ing Q dots using appropriate UV filters (605 nm) under a 
Nikon microscope, either in phase-contrast (panels on left) 
or fluorescence (panels on right) fields. Note that even a sin-
gle bacterium is visible in the B. cereus-Sterne field.BMC Biotechnology 2009, 9:67 http://www.biomedcentral.com/1472-6750/9/67
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tical nature of the cell wall surface as both these bacteria
are the monomorphic isolates within the B. cereus lineage
[4,20,21].
Our results clearly show that the 20-aa peptide PlyG-P1
(185GALTSLKMTADFILQSDGLT204), the 15-aa PlyG-P3
(185GALTSLKMTADFILQ199) and the 10-aa PlyG-P5
(190LKMTADFILQ199) consistently demonstrated selec-
tive binding to B. cereus-4342 and B. anthracis-Sterne in
the membrane based dot-blot method (detection level
103 CFU/ml). Though all three peptides were able to show
reactivity to the bacteria, the membrane assay does not
reveal the quantitative nature of this binding. Therefore,
this estimation was achieved by the ELISA and Fluorome-
try assays wherein it was further confirmed that the PlyG-
P1, PlyG-P3 and PlyG-P5 not only bound very efficiently
to B. cereus-4342 and B. anthracis-Sterne but in addition
there was a noticeable quantitative difference between
their binding capacity as well. Among the three peptides,
PlyG-P3 binding was significantly higher (P < 0.05) than
PlyG-P1 and PlyG-P5. The inability of the mutant pep-
tides PlyG-P2 (185GALTSAKMTADFILASDGLT204) and
PlyG-P6 (190AKMTADFILA199) binding to B. cereus-
4342 reaffirms a previous report that the L190 and Q199
residues within the binding motif 190LKMTADFILQ199
are critical in order for the larger PlyG protein to bind to
the bacterial cell wall [17]. However, it is interesting to
note that PlyG-P4 (190LKMTADFILQSDGLT204) lacking
five residues 185GALTS189 also demonstrated its inabil-
ity to bind to B. cereus-4342 and B. anthracis-Sterne. This
result suggest that while these five residues were not iden-
tified to be necessary for the binding of recombinant PlyG
156–223 protein to the bacteria in a previous report [17],
in the context of shorter synthetic peptide binding ability
to the bacteria, addition of these five residues to the N-ter-
minus of 190LKMTADFILQ199 sequence positively con-
tributed to the binding activity. This further suggests that
while 190LKMTADFILQ199 region (represented by PlyG-
P5 in this study) is a deemed essential motif of lysin PlyG
for its binding to the host cell wall, a peptide containing
additional five residues on the N-terminal side of this
minimum motif seems to be a better peptide for bioprobe
development. Fluorometric analysis indicated that PlyG-
P1 and PlyG-P3 were the strongest binders to B. cereus-
4342  and B. anthracis-Sterne. When combined with
Qdots, the detection sensitivity of PlyG-P3 was enhanced
to a single bacterium in the spiked plasma by florescence-
microscopy. These findings are encouraging and open up
novel strategies in the usage of some of these peptides
coupled with Qdots in developing diagnostics for B.
anthracis.
Conclusion
Our analysis of PlyG-derived synthetic peptides suggest
that three peptides (PlyG-P1, P3 and P5) selectively
bound to B. cereus-4342 and B. anthracis-Sterne, suggest-
ing the validity of using these peptides as bioprobes for
the detection of the two strains that serve as surrogates for
B. anthracis with respect to their cell wall binding capacity.
In addition, we identified a self-sufficient stand-alone bac-
terial cell-binding domain derived from the PlyG protein
to be useful as a bio-probe. The sensitivity of detection can
be enhanced by using Qdots in combination with the
peptides.
Methods
Cells, Reagents and Culture
The  Bacillus cereus strain (RSVF1 strain 4342), Bacillus
cereus ATCC 11778, Bacillus cereus ATCC10876, and Bacil-
lus thuringiensis ATCC 10792 were procured from the
American Type Culture Collection (ATCC, Manassas, VA).
Animal vaccine strain of B. anthracis (Sterne 34F2) origi-
nally obtained from Colorado Serum Co. (Denver, CO)
was a generous gift from Dr. Duncan, CBER, FDA. We uti-
lized brain-heart infusion (BHI) broth (Becton Dickinson,
Sparks, MD) for culturing this strain and Miller's Luria
Bertani (LB) broth (Mediatech Inc, Herndon, VA) for oth-
ers. All bacterial cultures were grown at 37°C.
Synthesis of PlyG peptides
Six varying lengths of peptides (named PlyG-P1 through
PlyG-P6) and ranging from 10 to 20 residues, represent-
ing amino acid position 185 to 204 encompassing the cell
wall binding essential domain of wild type PlyG and its
mutant forms were synthesized. The amino acid
sequences of the peptides were based on the previously
published amino acid sequence of PlyG C-terminal region
[17]. The peptides were synthesized at our Core Facility in
CBER, FDA, biotinylated with a C6-linker and purified by
High Pressure Liquid Chromatography (HPLC) for detec-
tion using a horse radish peroxidase (HRP)-conjugate
(Figure 1). Peptides were reconstituted in 100 mM NaPO4
and 150 mM NaCl, pH 7.2 buffer at room temperature to
a final concentration of 1 M. This stock solution was
diluted as needed for further use. We confirmed that all six
peptides to have the biotin linkers and are recognized by
steptavidin-HRP conjugate, prior to initiating the binding
assays.
Dot blot assay
5-ml early-log-phase culture of B. cereus-4342, B. cereus
ATCC 11778, B. cereus ATCC 10876, and B. thuringiensis
ATCC 10792 were grown in LB broth and B. anthracis-
Sterne was grown in BHI broth for 3 hr followed by cen-
trifugation at 3,000 × g. The cell pellet was resuspended
and 10-fold serial dilutions were made in 1× PBS (pH 7.4,
Mediatech Inc, Herndon, VA). Bacterial suspension (103
CFU/ml) was spotted directly onto a nitrocellulose mem-
brane essentially as described [16]. The membrane was
incubated in 5% bovine serum albumin (BSA) solution
(Sigma, St. Louis, MO) for 2 h to eliminate non-specific
signals on the membrane. Each membrane was incubatedBMC Biotechnology 2009, 9:67 http://www.biomedcentral.com/1472-6750/9/67
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separately with one peptide at a final concentration of 1.5
mM. Subsequently the membranes were washed three
times with TBST buffer (10 mM Tris-HCl, pH 7.5, 150 mM
NaCl, 0.05% Tween-20 (Aldrich Chemical Company, Mil-
waukee, WI). The membranes were then incubated with
1:10,000 diluted streptavidin-HRP conjugate (Upstate,
Temecula, CA) for 60 min at RT and washed three times
with TBST buffer. Following washing, the membrane was
developed using a DAB (3, 3'- diaminobenzidine) sub-
strate kit (Zymed Laboratories, Carlsbad, CA). The devel-
opment of colored spots in locations where the bacteria
were spotted on the membrane was inferred as positive for
peptide binding. The membranes were photographed for
archiving the data.
Enzyme-Linked ImmunoSorbent Assay (ELISA)
The assay was carried out as described previously [22]
with modifications. Briefly, 5-ml of early-log-phase bacte-
rial cultures of B. cereus-4342,  B. anthracis-Sterne,  B.
cereus-11778, B. cereus-10876, and B. thuringiensis were
centrifuged at 3,000 × g. The cell pellet was resuspended
and 10-fold serial dilutions were made in 1× PBS. Bacte-
rial cell suspension at a concentration of 103 CFU was
then layered into the wells of 96-well micro plate (Becton
Dickinson, Bedford, MA) and incubated overnight at RT.
Subsequently, cells were fixed in ethanol (Aldrich Chemi-
cal Company, Milwaukee, WI) for 10 min and the plates
were air-dried. Wells were blocked with 5% BSA (Sigma,
St. Louis, MO) for 60 min at RT, rinsed with PBS and then
PlyG peptides suspended in PBS at a final concentration
of 10 mM were added to all the wells and incubated for 15
min. Following incubation, wells were washed 3 times
with PBST buffer (PBS pH 7.4, 0.01% Tween 20). The
wells were further incubated with 1:10,000 dilution of
streptavidin-HRP conjugate (Upstate, Temecula, CA) for
15 min and washed with PBST buffer. Tetramethylbenzi-
dine (TMB) membrane peroxidase substrate (Zymed Lab-
oratories, Carlsbad, CA) system was used to detect the
enzyme label in accordance with the manufacturer's
instructions. The color development in the 96-well plate
was recorded by using Synergy 4™ BioTek micro plate
reader (BioTek Instruments, Winooski, VT) at 490 nm
wavelength. Assays were repeated three times for statisti-
cal analysis.
Q-dot based fluorescence assay
Log-phase cultures of B. cereus-4342, B. anthracis-Sterne,
B. cereus-11778, B. cereus-10876, and B. thuringiensis were
subjected to low-speed centrifugation and the pellet was
resuspended in 1 × PBS. Ten-fold serial dilutions were
each made in 1 ml of human plasma [23] and 103 CFU/
ml was used for spiking the plasma. The rationale for spik-
ing 103 CFU/ml of bacteria was based on the consensus in
the field, which suggests that the limit of detection for
commercially available rapid but less sensitive bacterial
detection systems is 103–105 CFU/ml (http://www.verax
biomedical.com). Peptide binding and detection assay
was performed in a final volume of 100 μl in an eppen-
dorf tube kept at RT for 90 min. Following the binding
step, tubes were centrifuged for 5 minutes at 3,000 × g and
the pellets were washed with PBS and resuspended in 100
μl of 1:10,000 diluted streptavidin-conjugated Q dots
(QD 605) solution (Invitrogen, Gaithersberg, MD). After
incubating for 90 min at RT, samples were centrifuged
again as above and the pellets were resuspended in 150 μl
of PBS. Samples were then placed on a glass slide (Mer-
cedes Medical, Sarasota, FL) or a micro well plate (Becton
Dickinson Lab ware, Bedford, MA) and analyzed either
under a fluorescence microscope [24] using Nikon Eclipse
TE2000-U (Nikon Instruments, Melville, NY) or by fluor-
ometry [25] using Synergy 4™ BioTek micro plate reader
(BioTek Instruments, Winooski, VT) respectively. Images
as visualized under the microscope were captured by an
intensified cooled charge-coupled device-equipped cam-
era (Nikon Eclipse TE2000-U).
Statistical analyses
We performed all assays described here in triplicates.
Mean values ± SD (Standard Deviation) were calculated
using Microsoft Excel®. Statistical analyses were performed
using Student's t test and values were considered signifi-
cant when P< 0.05.
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